Experimental Therapy for Rare Endocrine Disorder Offers Hope of Improved Care

Richard King, CEO of Spruce Biosciences, discusses the rare endocrine disorder CAH, how his company’s experimental therapy tildacerfont works, and what the company is doing to build a pipeline of other rare endocrine therapies behind it.